Insulin receptors in patients with insulinomas: changes in receptor affinity and concentration.
R S Bar, P Gorden, J Roth...
https://pubmed.ncbi.nlm.nih.gov/194912Actively Recruiting
Age: 18Years - 120Years
All Genders
ID00001276
Fasting Hypoglycemia: Diagnosis and Treatment
Led by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Updated on 2026-06-05
1500
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to improve understanding and treatment of fasting hypoglycemia, a condition characterized by low blood sugar levels, caused by various factors such as insulinomas and other pancreatic tumors. The study focuses on learning about the causes, identifying new blood markers for insulinomas, and creating a collection of clinical data and samples for future research. Participants diagnosed with fasting hypoglycemia will be admitted to the Clinical Center of the National Institutes of Health for evaluation and treatment according to standard care practices. During the study, patients will undergo tests including fasting blood sugar measurements and insulin level assessments to understand their specific condition better. Throughout the study, participants will be monitored regularly, with treatment outcomes assessed every 1 to 3 months. They will receive medical and surgical care as needed, and the research team will collect detailed clinical information and blood samples to support ongoing and future investigations into hypoglycemia and insulinomas.
CONDITIONS
Brief Title
Diagnosing and Treating Low Blood Sugar Levels
Who Can Participate
Age: 18Years - 120Years
All Genders
Eligibility Criteria
You may qualify if you...
- Male or female aged 18 years or older
- Documented fasting blood glucose below 55 mg/dl
- Biochemical evidence of insulinoma or other pancreatic neuroendocrine tumors
You will not qualify if you...
- Significant cardiac disease
- Pregnant women (self-reported)
- Medically unstable as assessed by the principal investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Diagnostic Evaluation
Duration - Varies according to individual diagnostic needs
Participants undergo evaluation to diagnose the cause of fasting hypoglycemia, including assessment for insulinomas and related conditions.
Monitoring
Duration - Ongoing with assessments every 1 to 3 months
Participants with diagnosed hypoglycemia are observed and their treatment outcomes are assessed.
Visits every 1 to 3 months
Trial Site Locations
Total: 1 location
1
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892
Actively Recruiting
Loading map...
Research Team
C
Craig S Cochran, R.N.
R
Ranganath Muniyappa, M.D.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Reactive hypoglycemia and insulin autoantibodies in drug-induced lupus erythematosus.
P J Blackshear, H E Rotner, K A Kriauciunas...
https://pubmed.ncbi.nlm.nih.gov/6349454Approach to hypoglycemia in adults.
R J Comi, P Gorden
https://pubmed.ncbi.nlm.nih.gov/3568598